arrow
M

Miguel A. Escobar

Gulf States Hemophilia and Thrombophilia Center
H指数:32
被引数:3,665

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recommendations for harmonizing definition, recording and reporting of the annual bleeding rate (ABR) in hemophilia: Communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders."

关于协调血友病年度出血率(ABR)定义、记录和报告的建议:来自ISTH SSC凝血因子VIII、凝血因子IX和罕见凝血障碍分委员会的通讯。

2026-09-090
PRE
Correction: Future Circular Collider Feasibility Study Report

更正:未来环形对撞机可行性研究报告

2025-11-190
OAAI
Future circular collider feasibility study report

未来环形对撞机可行性研究报告

2025-11-170
OA
The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025

《WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025》

2025-10-250
OAAI
Future Circular Collider Feasibility Study Report

未来环形对撞机可行性研究报告

2025-10-130
OA
Calidad de vida en pacientes post-COVID-19 tras el alta de un centro de desvinculación de ventilación mecánica y rehabilitación: estudio de cohorte retrospectivo

COVID-19后患者的生活质量:机械通气脱离与康复中心出院后的回顾性队列研究

2025-06-280
PRE
A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A

对多效性免疫介导疾病基因的扫描识别出血友病A中基础FVIII抑制剂状态的新的决定因素

2025-04-220
PRE
Disentangling effects of the DR and DQ isomers encoded by the HLA class II haplotype DRB1*15:01/DQB1*06:02 to help establish the true risk allele for FVIII inhibitor development in Hemophilia A

区分由HLA-II类单倍型DRB1*15:01/DQB1*06:02编码的DR和DQ异构体的效应,以帮助确定血友病A中FVIII抑制剂发展的真实风险等位基因。

2025-04-090
OA
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
2024-12-090
PRE
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal
2024-12-060
PREAI